key: cord-0319482-fpa6enje
authors: Kulkarni, Rakesh; Chen, Wen-Ching; Lee, Ying; Kao, Chi-Fei; Hu, Shiu-Lok; Ma, Hsiu-Hua; Jan, Jia-Tsrong; Liao, Chun-Che; Liang, Jian-Jong; Ko, Hui-Ying; Sun, Cheng-Pu; Lin, Yin-Shoiou; Wang, Yu-Chiuan; Wei, Sung-Chan; Lin, Yi-Ling; Ma, Che; Chao, Yu-Chan; Chou, Yu-Chi; Chang, Wen
title: Vaccinia virus-based vaccines confer protective immunity against SARS-CoV-2 virus in Syrian hamsters
date: 2021-08-03
journal: bioRxiv
DOI: 10.1101/2021.08.03.454910
sha: 708d6a0060fa96f5429a23ada0c9901a7b1100cb
doc_id: 319482
cord_uid: fpa6enje

COVID-19 in humans is caused by Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) that belongs to the beta family of coronaviruses. SARS-CoV-2 causes severe respiratory illness in 10-15% of infected individuals and mortality in 2-3%. Vaccines are urgently needed to prevent infection and to contain viral spread. Although several mRNA- and adenovirus-based vaccines are highly effective, their dependence on the “cold chain” transportation makes global vaccination a difficult task. In this context, a stable lyophilized vaccine may present certain advantages. Accordingly, establishing additional vaccine platforms remains vital to tackle SARS- CoV-2 and any future variants that may arise. Vaccinia virus (VACV) has been used to eradicate smallpox disease, and several attenuated viral strains with enhanced safety for human applications have been developed. We have generated two candidate SARS-CoV-2 vaccines based on two vaccinia viral strains, MVA and v-NY, that express full-length SARS-CoV-2 spike protein. Whereas MVA is growth-restricted in mammalian cells, the v-NY strain is replication-competent. We demonstrate that both candidate recombinant vaccines induce high titers of neutralizing antibodies in C57BL/6 mice vaccinated according to prime-boost regimens. Furthermore, our vaccination regimens generated TH1-biased immune responses in mice. Most importantly, prime-boost vaccination of a Syrian hamster infection model with MVA-S and v-NY-S protected the hamsters against SARS-CoV-2 infection, supporting that these two vaccines are promising candidates for future development. Finally, our vaccination regimens generated neutralizing antibodies that partially cross-neutralized SARS-CoV-2 variants of concern.

priming with v-NY-S alone generated neutralizing antibodies against SARS-CoV-2 248 virus in a dosage-dependent manner (Fig. 7B ). Then we performed challenge 249 experiments and monitored SARS-CoV-2 virus titers in lungs at 3 d.p.i. (Fig. 7C) . 250

Virus titers were ~10 6 PFU/animal in the placebo-infected group, but virus titers were 251 >100-fold lower in hamsters subjected to single immunization with v-NY-S at either 252 dosage (1x10 7 or 5x10 7 PFU/animal), showing that single immunization had already 253 provided partial protection against SARS-CoV-2 infection. Upon removing lungs for 254 histological examination, we observed that the placebo-infected group presented a 255 severe pathological phenotype including diffuse congestion, shrinking of alveoli, 256

hemorrhaging, and mononuclear cell infiltration (Fig. 7D , open arrowheads). 257

Moreover, immunostaining for SARS-CoV-2 NP protein also revealed widespread 258 peribronchiolar immunoreactivity (Fig. 7D , arrowheads) in the lungs of the placebo 259 group. In contrast, the lung pathology of the vNY1-infected (Fig. 7E ) and vNY5-260 infected (Fig. 7F ) groups was much milder than observed for the placebo-infected 261 group, displaying lower immune cell infiltration, rare epithelial degeneration and an 262 absence of vasculitis/endothelialitis. Viral NP immune signal in lung tissues was also 263 significantly lower in the vNY1 and vNY5 groups relative to the placebo group 264 (rightmost panels in Fig. 7E & 7F) . 265 266 Sera from vaccinated mice partially cross-neutralize SARS-CoV-2 variants of 267 concern. 268 Recently, circulation of new SARS-CoV-2 variants of concern (VOC) has become 269 prevalent, entailing a risk of increasing resistance to the neutralizing antibodies 270 generated by SARS-CoV-2 vaccines. Accordingly, we used pseudotyped SARS-CoV-271 their ability to cross-neutralize SARS-CoV-2 variants (Fig. 8) . Although statistical 273 analyses did not reveal a significant neutralization difference among the three 274 immunization regimens to each variant, the mean neutralization titers of the α and γ 275 variants were similar to that of the wild type whereas the mean titers of β, B.1.617 276 and δ variants appeared much lower than the wild type (Fig. 8A) . For We wanted to explore other prime-boost combinations involving v-NY-S as an 292 alternative strategy to improve immune responses. As shown in Fig. 9A , unlike 293 MVA5/MVA1 ( Figure 2C ), prime-boosting with a homologous vNY1/vNY1 strategy 294 did not increase anti-spike antibody titers after boosting (Fig. 9A ). We rationalize that 295 homologous prime-boosting with a replicating virus such as v-NY-S is not a good 296 immunization strategy. Interestingly, heterologous priming with v-NY-S at 1x10 7 enhanced anti-spike antibody titers ( Figure 9A ) and neutralizing activity ( Figure 9B) . 299

In addition, we compared the route of priming between skin scarification 300 (vNY1/MVA1) and intranasal inoculation (vNY0.1/MVA1) for v-NY-S and found 301 that the latter route generated higher anti-spike antibody levels ( Figure 9A ) and 302 neutralizing activity ( Figure 9B ) with only 1/10 of virus inoculum. These data are 303 very encouraging and will aid in future vaccination strategies. Discussions are 304 ongoing as to whether heterologous prime-boosting of COVID vaccines elicits more 305 potent immune responses than a homologous prime-boost strategy (71-73). We argue 306 that mix-and-match vaccination strategies are an important consideration for 307 designing the next generation of SARS-CoV-2 vaccines. against SARS-CoV-2, and also generated a TH1-biased T cell response that can 315 promote pathogen clearance. Importantly, we have demonstrated that our vaccination 316 regimens protected Syrian hamsters (representing an appropriate animal model of 317 SARS-CoV-2-induced respiratory disease in human) from weight loss, elicited rapid 318 clearance of SARS-CoV-2 virus, and reduced immune infiltrates in lung tissue. 319

Previous studies have revealed that virus shedding is often associated with a high viral 320 titer in lung tissues (42, 54, 68). Bricker et al. (2021) showed that virus titers in 321 vaccinated hamsters were cleared by day 3, and no virus shedding was detected in vaccinated transgenic mice did not shed virus as early as day 2 when virus was 324 cleared from the lungs (42). Since virus was cleared from the lung tissue of our prime-325 boost vaccinated animals, it is likely that virus shedding in these animals is limited. 326

When we compared data from male versus female hamsters in terms of weight loss 327 and virus replication in lungs, we did not observe noticeable sex-associated 328 differences in these hamsters after challenge with SARS-CoV-2 virus. Interestingly, 329 Dhakal et al. (2021) reported that hamsters of both sexes exhibited similar weight 330 loss, virus titers in lungs and cytokine response in the first 5-7 days after SAS-CoV-2 331 challenge (74). However, they also showed that, starting from day 7 up to 4 weeks, 332

female hamsters developed greater antibody responses and recovered from weight 333 loss faster than male hamsters (74). Because all our experiments were terminated 334 within 1 week after SARS-CoV-2 challenge it could explain a lack of sex-associated 335 difference in our experiments. 336

Hamster is a good animal model of SARS-CoV-2 with several advantages. It is 337 suitable to study virus replication and transmission by contact and aerosols (75, 76). 338

Most of hamsters infected with SARS-CoV-2 do not die, which is consistent with 339 human infections, and the pathological features of the lungs in the infected animals 340 resemble those observed in COVID-19 patients (77-79). Hamster is relatively low 341 cost when compared with other animal models, such as ferrets (80) and non-human 342 primates (81), and has been shown to mount an effective antibody response that clears 343 virus within one week, making it a suitable model to study vaccine efficacy and Table 1 

To generate recombinant vaccinia viruses expressing SARS-CoV-2 S protein plasmid and under regulatory control by an early and late p7.5k promoter to obtain 471 the virus stocks were partially purified using a 36% sucrose gradient and titrated prior 480 to use, as described previously (118). for both priming and boosting shots. Blood was collected from immunized mouse 516 cheeks 4 weeks after priming and 2 weeks after boosting, as described previously 517

(120, 121). Sera were prepared from blood and saved at -80 °C until use. 

Lentiviral vectors pseudotyped with spike protein of wild type SARS-CoV-2 and 589 SARS-CoV-2 variants of concern (VOC) ( Table 2 ) were generated and titered by the 590 National RNA Technology Platform and Gene Manipulation Core, Academia Sinica, 591

Taipei, Taiwan. Neutralization assays on pseudotyped virus were performed by the 592 same core facility as described previously (122), but with minor modifications. In 593 brief, 1,000 units of the pseudotyped lentivirus with SARS-CoV-2 S protein were incubated at 37 °C for 1 h with serially-diluted sera obtained from vaccinated animals. 595

The mixture was then added to HEK-293T cells expressing human ACE2 receptor 596 (10 4 cells/well of a 96-well plate) and incubated for 24 h at 37 °C. This cell culture 597 was then replaced with 100 μl of fresh DMEM plus 10% FBS, and the cells were 598 incubated for another 48 h before undergoing luciferase assay. The reciprocal dilution 599 of serum required for 50% inhibition of virus infection (ND50) was assessed by 600 measuring luciferase intensity. 601 

Serially diluted antibodies from immunized mice or hamsters were incubated at 37 606 °C for 1 h with 100 TCID50 SARS-CoV-2 TCDC#4 (hCoV-19/Taiwan/4/2020). The 607 mixtures were then added to pre-seeded Vero E6 cells for a 4-day incubation. Cells 608 were fixed with 10% formaldehyde and stained with 0.5% crystal violet for 20 min. 

A pneumonia 727 outbreak associated with a new coronavirus of probable bat origin

Coronaviridae Study Group of the International Committee on Taxonomy of

The species Severe acute respiratory syndrome-related coronavirus: classifying 731 2019-nCoV and naming it SARS-CoV-2

Comparing SARS-CoV-2 with SARS-CoV and influenza pandemics

Genomic 742 characterization of the 2019 novel human-pathogenic coronavirus isolated from a 743 patient with atypical pneumonia after visiting Wuhan

Characteristics of SARS-CoV-2 and COVID-746 19

Cell entry 748 mechanisms of SARS-CoV-2

Molecular interaction and inhibition of SARS-CoV-2 binding to the ACE2 receptor

Structures and 753 distributions of SARS-CoV-2 spike proteins on intact virions

SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and

Human neutralizing 761 antibodies elicited by SARS-CoV-2 infection

Candidate 763 Targets for Immune Responses to 2019-Novel Coronavirus (nCoV): Sequence

Sequence Homology and Bioinformatic Approach Can Predict Candidate Targets for

Immune Responses to SARS-CoV-2

Thermostable mRNA Vaccine against COVID-19

SARS-CoV-2 mRNA vaccine design enabled by prototype 772 pathogen preparedness

BNT162b vaccines protect rhesus macaques from SARS-CoV-2

Single-shot Ad26 vaccine protects against SARS-CoV-2 in rhesus macaques

Safety and immunogenicity of an rAd26 and rAd5 vector-780 based heterologous prime-boost COVID-19 vaccine in two formulations: two open, 781 non-randomised phase 1/2 studies from Russia

et 915 al. Immunogenicity and protective efficacy of BBV152

SARS-CoV-2 vaccine candidates in the Syrian hamster model

Animal models for COVID-19

Simulation of 921 the Clinical and Pathological Manifestations of Coronavirus Disease

Inoculation Establishes Subclinical Respiratory Infection with Virus Shedding in

A 928 single intranasal or intramuscular immunization with chimpanzee adenovirus-929 vectored SARS-CoV-2 vaccine protects against pneumonia in hamsters

Mix-and-match COVID vaccines: the case is growing, but questions 942 remain

Mix-and-match COVID vaccines trigger potent immune 944 response

Sex differences in lung imaging and SARS-CoV-2 antibody responses in a COVID

golden Syrian hamster model. bioRxiv. 2021. 948 75

Pathogenesis and transmission of SARS-CoV-2 in golden hamsters

Simulation of the Clinical and Pathological Manifestations of Coronavirus Disease 953 2019 (COVID-19) in a Golden Syrian Hamster Model: Implications for Disease 954

Syrian hamsters as a small animal model for SARS-CoV-2 infection and SARS-2-S in preclinical vaccination

Early 991 induction of functional SARS-CoV-2-specific T cells associates with rapid viral 992 clearance and mild disease in COVID-19 patients

Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates

NVX-CoV2373 vaccine protects cynomolgus macaque upper and lower airways 998 against SARS-CoV-2 challenge

Vaccinia virus: a selectable eukaryotic cloning 1000 and expression vector

Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS

CoV-2: a preliminary report of a phase 1/2, single-blind

Structure-based design of prefusion-stabilized SARS-CoV-2 spikes

Absence of vaccine-1015 enhanced disease with unexpected positive protection against SARS-CoV-2 by 1016 inactivated vaccine given within three days of virus challenge in Syrian hamster 1017 model

Characterization of a recombinant vaccinia virus expressing human melanoma-1020 associated antigen p97

NYVAC: a highly attenuated strain of vaccinia virus

Protection of 1024 macaques against simian AIDS by immunization with a recombinant vaccinia virus 1025 expressing the envelope glycoproteins of simian type D retrovirus

Oral 1028 Immunization with Recombinant Vaccinia Virus Prime and Intramuscular Protein 1029

Boost Provides Protection against Intrarectal Simian-Human Immunodeficiency Virus 1030 Challenge in Macaques

Safety and 1041 immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: interim results 1042 from a double-blind, randomised, multicentre, phase 2 trial, and 3-month follow-up of 1043 a double-blind

Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine

A thermostable mRNA vaccine against

Phase 1-2 Trial 1053 of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine

Proliferative and cytotoxic T cells to AIDS virus glycoproteins in chimpanzees 1067 immunized with a recombinant vaccinia virus expressing AIDS virus envelope 1068 glycoproteins

Processing, Assembly, and Immunogenicity of Human-Immunodeficiency-Virus Core

Antigens Expressed by Recombinant Vaccinia Virus

Generation of Recombinant Vaccinia Viruses

Preparation of Cell Cultures and 1075

Vaccinia Virus Stocks

Vaccinia virus expression vector: 1077 coexpression of beta-galactosidase provides visual screening of recombinant virus 1078 plaques

Reply to 1080

The gingival vein as a minimally traumatic site for multiple blood sampling in 1090 guinea pigs and hamsters

Development of CpG-adjuvanted stable prefusion SARS-CoV-2 spike antigen as a 1093 subunit vaccine against COVID-19

Determination of 50% endpoint titer using a simple 1095 formula

CoVaccine HT Adjuvant Potentiates Robust Immune Responses to Recombinant 1098 SARS-CoV-2 Spike S1 Immunization

Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR

B) Weight change in Syrian hamsters after immunization with 1109 one of the three regimens

The dotted 1113 line represents assay limits of detection

Surface detection of SARS-CoV-2 S protein expressed from MVA

BHK21 and BSC40 cells were infected with MVA-S (blue line) or v-1122 NY-S (red line), respectively, harvested at 12 hours post-infection (hpi), stained with 1123 anti-RBD antibody, and then analyzed by flow cytometry. (C). Immunofluorescence 1124 staining of SARS-CoV-2 S protein in cells infected with

Immunoblot 1128 of SARS-CoV-2 S protein expressed by MVA-S and v-NY-S. BHK21 cells were 1129 infected with MVA or MVA-S; BSC40 cells were infected with v-NY or v-NY-S, 1130 respectively

CoV-2-specific IgG antibodies by flow cytometry using SF9 cells infected with either

Quantification of anti-spike antibody titers in 1° and 2° sera from 1142 mice (as shown in B) using the mean fluorescence intensity (MFI) value from FACS

Numbers of mice for 1° and 2° sera collection are identical: PBS vs

MVA5 vs. MVA5/MVA1 (n=5); vNY1 vs. vNY1/MVA1 (n=5), and vNY5 vs

Data are represented as mean ± SD. **p<0

Immunoblot analyses of recombinant SARS-CoV-2 S protein 1147 using 1° and 2° sera (1:100) from immunized mice. A single representative serum is 1148 shown in each blot. (E). Neutralization assays of 2° sera collected from vaccinated 1149 mice using (i) Pseudovirus and (ii) SARS-CoV-2 virus infection

The dotted 1151 line represents assay limits of detection

Quantification of 1152 anti-spike antibodies in mouse sera collected at 0.5 and 4.5 months after vaccination 1153 regimens using SF9 cells infected with WT-BAC or S-BAC

Pseudovirus neutralization assay using mouse sera collected at 1155 0.5 months and 4.5 months after vaccination regimens

ns -not significant. *p<0.05. The for their expression of IL-2, IFN-γ, TNF-α, IL4 and IL6 cytokines (n=5 for each 1166 group). Data represented as mean ± SEM. SFC -spot-forming cells

SARS-CoV-2 spike-specific CD8 + (in D) and CD4 + 1168 (in E) T effector memory cells (CD44 + CD62L -) in splenocytes, as detected by flow 1169 cytometry (n=5 for each group). Data represented as mean ± SD. ns -not significant

Data are represented as mean ± SD. ****p<0.0001. (D)

:20) from immunized hamsters using recombinant SARS-CoV-2 S vNY1/MVA1 (n=10); and vNY5/MVA1 (n=10). The dotted line represents assay 1190 limits of detection

Hamsters subjected to the MVA5/MVA1, vNY1/MVA1 or v-NY5/MVA1 1193 vaccination regimens were protected against intranasally-administered SARS

Timeline of the immunization and challenge experiments

Hamsters immunized with one of three prime-boost vaccination regimens 1196 (MVA5/MVA1, vNY1/MVA1 or vNY5/MVA1), or placebo (PBS) as a control, were 1197 challenged i.n. with 1x10 5 PFU SARS-CoV-2 virus

Weight change of hamsters within 3 days of SARS-CoV-2 challenge. Data 1199 represented as mean ± SEM. *p<0.05. (C). TCID50 value of SARS-CoV-2 in lung 1200 tissue of hamsters at 3 d.p.i. after SARS-CoV-2 challenge

Timeline of the immunization and 1203 challenge experiments. Hamsters immunized with one prime-boost vaccination 1204 regimen (MVA5/MVA1), or placebo (PBS/PBS) as a control, were challenged i.n. 1205 with 1x10 5 PFU SARS-CoV-2 virus

H&E staining showed severe 1216 bronchointerstitial pneumonia with the alveolar walls thickened by edema, capillary 1217 congestion and variable immune cell infiltration (open arrowheads). The vascular 1218 endothelia were frequently disrupted by immune infiltrates (vasculitis/endotheliolitis, 1219 black arrows). Immunohistochemistry of SARS-CoV-2 NP protein revealed 1220 prominent peribronchiolar staining (arrow heads)

Compared to the placebo 1223 (PBS/PBS) infection hamster group, lung architecture was better preserved, there was 1224 much less immune cell infiltration, and SARS-CoV-2 NP staining signal was barely 1225 detectable. (E). H&E and immunohistochemical staining of lungs of the placebo 1226 (PBS/PBS) infection hamster group at 7 d.p.i.. H&E staining revealed prominent type 1227 II pneumocytic hyperplasia

Immunohistochemistry of SARS-CoV-2 NP protein detected dispersed positive 1229 signals at the edges of regenerative foci. (F). MVA5MVA1-immunized hamsters 1230 displayed minimal lung pathology and scant SARS-CoV NP immunolabeling at 7

Data represented as mean ± SD. The dotted line 1241 represents assay limits of detection. *p<0.05. (C). TCID50 values for lungs from 1242 hamsters of the placebo (PBS)

Data represented as mean ± SD. The dotted line 1244 represents assay limits of detection. ns-not significant. (D). H&E and 1245 immunohistochemical staining of lungs of the placebo (PBS) infection hamster group 1246 at 3 d.p.i.. H&E staining revealed an identical pathology to that shown in Figure 6A, 1247 revealing severe bronchointerstitial pneumonia with the alveolar walls thickened by 1248 edema

H&E and immunohistochemical staining 1252 of hamster lungs primed with vNY1 (in E) or vNY5 (in F) at 3 d.p.i.. The lung 1253 architecture was largely preserved, displaying reduced immune cell infiltration 1254 relative to the placebo infection group and SARS-CoV-2 NP protein was barely 1255 detectable by immunohistochemistry